TGTX

Business Context and Reporting Period

Company: Manhattan Pharmaceuticals, Inc. (Note: Filing metadata referenced "TG THERAPEUTICS, INC." but the document content identifies the registrant as Manhattan Pharmaceuticals, Inc.)
Reporting Period: Quarterly period ended June 30, 2011 (Form 10-Q)
Business Stage: Development stage biopharmaceutical company with no product revenues.
Key Events: The Company completed a 1-for-50 reverse stock split on June 20, 2011. It operates primarily through the development of product candidates AST-726 (Vitamin B12 deficiency) and AST-915 (essential tremor), acquired via the 2010 merger with Ariston Pharmaceuticals, Inc.

Key Financial Metrics

Cash Flow: Net cash provided by operating activities was $113,840 for the six months ended June 30, 2011. Net cash used in financing activities was $(100,000).

Material Changes vs. Prior Period

• Net Income Volatility: The Company reported a net income of $849,844 for the six months ended June 30, 2011, compared to $217,167 in the same period in 2010. However, the three-month period ended June 30, 2011, resulted in a net loss of $(2,982,539) compared to net income of $1,850,336 in the prior year quarter.
• Non-Cash Gain: The six-month net income was driven primarily by a non-cash gain of $4,517,488 from the "Nordic Settlement," which resolved disputes with Nordic Biotech Ventures regarding a joint venture.
• Derivative Liability: The derivative liability increased significantly from $534,846 at December 31, 2010, to $2,639,728 at June 30, 2011, due to changes in fair value and warrant amendments triggered by the reverse stock split.
• Expense Reduction: General and administrative expenses decreased by approximately 55% year-over-year for the six-month period, attributed to staff reductions and cost-cutting measures.
• Debt Structure: The Company extended the maturity of its Secured 12% Notes to December 31, 2011, and amended terms to allow conversion to equity at $0.50 per share.

Guidance, Outlook, Risks, and Unusual Items

• Liquidity and Going Concern: Management states there is "substantial doubt" about the Company's ability to continue as a going concern. Cash on hand ($492,508) is sufficient only through the end of 2011. Additional financing is required to sustain operations into 2012 and fund clinical trials.
• Debt Maturities: $250,000 of debt matures in November 2011, and $1,725,000 (plus interest) matures in December 2011. The Company intends to convert the December debt into equity.
• Unusual Items: The $4.5 million gain on the Nordic Settlement is a non-recurring, non-cash item. Without this gain, the Company would have reported a loss for the six-month period.
• Legal Proceedings: The Hedrin Joint Venture (in which the Company holds a 15% interest) is involved in arbitration with Thornton & Ross, Ltd. The JV seeks $7 million in damages, while the counterparty seeks $20 million in damages against the JV and the Company.
• Internal Controls: The Company disclosed that its disclosure controls and procedures were not effective as of June 30, 2011, because all financial and accounting duties were performed by a single individual.

Investor Verification Checklist

• Capital Adequacy: Verify the status of fundraising efforts required to bridge the funding gap beyond December 2011.
• Debt Conversion: Confirm the execution of the conversion of the $1.725 million Secured 12% Notes into equity to avoid default.
• Legal Exposure: Monitor the outcome of the arbitration between the Hedrin JV and Thornton & Ross, Ltd., specifically the $20 million counterclaim against the Company.
• Derivative Liability: Assess the impact of the $2.6 million derivative liability on future earnings and potential dilution from warrant exercises.
• Internal Controls: Review the Company's plan to remediate the ineffective internal controls over financial reporting.